A Single-Center Retrospective Cohort Study of Yinqiao Piwen Powder for the Treatment of Patients with Mild Corona Virus Disease 2019
10.16466/j.issn1005-5509.2024.12.006
- VernacularTitle:银翘辟瘟散治疗轻型新型冠状病毒感染的单中心回顾性队列研究
- Author:
Qianqian ZHAO
1
;
Xiujie LYU
;
Hanxiao LYU
Author Information
1. 浙江中医药大学第一临床医学院 杭州 310053
- Publication Type:Journal Article
- Keywords:
mild COVID-19 infection;
Yinqiao Piwen Powder;
single-center retrospective cohort study;
treatment based on syndromes differentiation;
combination of TCM and western medicine;
TCM syndromes;
prevent and cure blight;
evidence-based medicine
- From:
Journal of Zhejiang Chinese Medical University
2024;48(12):1517-1524
- CountryChina
- Language:Chinese
-
Abstract:
[Objective]To evaluate the effectiveness of Yinqiao Piwen Powder,an empirical formula,in the treatment of mild cases of corona virus disease 2019(COVID-19) infection.[Methods]A single-center retrospective cohort study was adopted. A total of 595 patients with mild COVID-19 infection who attended Zhejiang Provincial Hospital of Traditional Chinese Medicine from December 18 to 23,2022 were included in this study and then divided into western medicine group (WM),traditional Chinese medicine group (TCM) and integrated Chinese and western medicine group (TCM-WM) based on their medication,with 153 cases,144 cases and 298 cases in each respectively. The WM group received routine treatment of western medicine according to the Diagnosis and Treatment Protocol for COVID-19 Patients (Tentative 10th Edition),the TCM group received Yinqiao Piwen powder treatment,and the TCM-WM group received Yinqiao Piwen Powder treatment on the basis of the treatment of the WM group. After 14 days,the therapeutic effect of patients was evaluated. Specifically,the baseline characteristics,clinical symptoms and symptom relief time of the patients were collected,the TCM symptom scores were estimated,and the distribution of symptoms and efficacy distribution after treatment in each group were analyzed.[Results]The most common symptoms in patients with mild COVID-19 infection were fever,cough,sputum,fatigue,body aches,sore throat,nasal congestion and runny nose. On the efficacy distribution,the markedly effective rate of the TCM-WM group was significantly higher than that of the WM group,which were both significantly different(x2=14.022,P<0.001) After treatment,the total TCM symptom scores of all three groups were significantly decreased compared with pre-treatment,indicating a great relief in the clinical symptoms in all groups,with a statistically significant difference (P<0.001). Additionally,the median number of the rate of reduction of TCM symptom scores in the TCM-WM group was 100.00(93.21,100.00),higher than the TCM group[100.00(92.15,100.00)]and the WM group[100.00(78.95,100.00)],and showed statistical difference (P<0.05). The differences of TCM symptom scores of three groups between the pre-treatment and post-treatment were significant (P<0.05),and the TCM-WM group changed the most in the scores. Besides,after correction for age and pre-treatment symptom scores,the differences in post-treatment TCM symptom scores among the three groups were still statistically significant ( P<0.05). Moreover,the differences among the three groups in the symptom relief time of sore throat,cough,sputum and fatigue were statistically significant(P<0.05).[Conclusion]Compared with the western medicine treatment alone,the other two treatments achieved better clinical results in improving the efficacy,reducing the TCM symptom scores and shortening the symptom relief time. The results of our study can provide evidence-based medical proof for the benefits of TCM in the prevention and treatment of epidemics.
